OncLive TV

Nancy U. Lin, MD, discusses the development of systemic therapies for the treatment of patients with metastatic HER2-positive breast cancer and brain metastases.

Paolo Ghia, MD, PhD, discusses the efficacy and safety of acalabrutinib in the phase 3 ASCEND trial in relapsed/refractory chronic lymphocytic leukemia.

Gaël Roué, PhD, discusses interest regarding the novel irreversible inhibitor TG-1701 in models of ibrutinib (Imbruvica)-resistant mantle cell lymphoma.

Lori A. Leslie, MD, discusses the benefits with zanubrutinib (Brukinsa) in the treatment of patients with mantle cell lymphoma.

Katja Weisel, MD, discusses the interim analysis of the phase 2 GMMG-Concept trial with isatuximab-irfc in combination with carfilzomib, lenalidomide, and dexamethasone in high-risk patients with newly diagnosed multiple myeloma.

Aaron E. Katz, MD, FACS, discusses redefining risk stratification for men with prostate cancer.

Matthew S. Davids, MD, MMSc, discusses updated findings from a phase 1/1b study which examined the combination of ibrutinib (Imbruvica) and umbralisib in relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma.

Jesus G. Berdeja, MD, discusses the dosing of the investigational CAR T-cell product JNJ-4528 in patients with ​relapsed/refractory multiple myeloma.

​Neal D. Shore, MD, FACS, discusses the potential benefits of the immunotherapy INO-5150 for patients with biochemically recurrent prostate cancer.

Tanios S. Bekaii-Saab, MD, FACP, discusses second-line treatment options in hepatocellular carcinoma.

Eric Jonasch, MD, discusses the safety profile of the investigational oral hypoxia-inducible factor-2α inhibitor MK-6482 in Von Hippel-Lindau disease–associated renal cell carcinoma.

Scott Kopetz, MD, PhD, FACP, discusses the rationale for the phase 3 BEACON CRC trial in BRAF V600E-mutant metastatic colorectal cancer.

Chetasi Talati, MD, discusses the design of a chart review study with venetoclax and hypomethylating agents in older patients with newly-diagnosed acute myeloid leukemia.

Thomas A. Hope, MD, discusses the positive findings from a phase 3 imaging study, which utilized 68Ga-PSMA-11 PET in the detection of pelvic nodal metastasis in men with intermediate- or high-risk prostate cancer.

Neal D. Shore, discusses the potential utility of relugolix in patients with advanced prostate cancer.

Ritu Salani, MD, MBA, discusses the current state of biomarker testing in cervical cancer.

Christian U. Blank, MD, PhD, discusses adjuvant versus neoadjuvant approaches in macroscopic stage III melanoma.

Shilpa Gupta, MD, discusses challenges with ​perioperative immunotherapy in bladder cancer.

Jennifer K. Litton, MD, discusses the phase 3 EMBRACA trial in patients with germline BRCA1/2-mutated metastatic HER2-negative breast cancer. 

Sattva Neelapu, MD, discusses the potential advantages of allogeneic CAR T-cell therapy compared with autologous CAR T-cell therapy in lymphoma.

Ronald Hoffman, MD, discusses the advantages of self-administration with the investigational hepcidin mimetic PTG-300 for patients with polycythemia vera (PV).

Jia Ruan, MD, PhD, discusses some of the unanswered questions regarding optimizing treatment selection in patients with mantle cell lymphoma.

Marc J. Braunstein, MD, PhD, discusses the utility of maintenance therapy in patients with multiple myeloma.

Salvatore Siena, MD, provides an overview of the DESTINY-CRC01 trial ​in DESTINY-CRC01 trial in HER2-positive metastatic colorectal cancer.

Jamie E. Chaft, MD, discusses predictive biomarkers in lung cancer.

Andrew Yee, MD, discusses the utility of isatuximab-irfc in relapsed/refractory multiple myeloma.

Nikhil C. Munshi, MD, discusses the next steps for research with idecabtagene vicleucel in relapsed/refractory multiple myeloma.

Sander Bach, MD, PhD, ​discusses the rationale to conduct a systematic review of circulating tumor DNA in colorectal cancer.

Nikhil C. Munshi, MD, discusses T-cell persistence with ​idecabtagene vicleucel demonstrated in the phase 2 KarMMA trial in patients with relapsed /refractory multiple myeloma.

Matthew S. Davids, MD, MMSc, discusses the rationale for examining ibrutinib in combination with umbralisib in relapsed/refractory chronic lymphocytic leukemia or mantle cell lymphoma.